Please assess the completion status of the following clinical trial:

Trial Title: Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has essential hypertension who is in grade 1 or 2 hypertension according to the European Society of Hypertension (ESH) as delineated in the European Society of Cardiology (ESC) 2007 guidelines, i.e. systolic blood pressure values of 140-179 and diastolic blood pressure values of 90-109 on at least 3 occasions prior to the study.~* Otherwise healthy participants with grade 1 or 2 arterial hypertension who are treated with a single antihypertensive drug and meet the above blood pressure criteria may be enrolled at the discretion of the investigator~* Participant is generally in good health with the exception of hypertension~* Participant is a nonsmoker and/or has not used nicotine or nicotine-containing products for 6 months~Exclusion Criteria:~* Participant has a history of any illness that might confound the results of the study or pose and additional risk to the participant if they take part in the study~* Participant has a history of stroke, chronic seizures, or major neurological disorder~* Participant has a disability that can interfere with rising from a semi-recumbent position to the standing position~* Participant has a personal or family history of a bleeding or clotting disorder~* Participant has a history of frequent nosebleeds or recurrent or active gingivitis~* Participant has a history of cancer, except 1) certain skin cancers; 2) cancer successfully treated more than 10 years prior to the study that has not recurred; or, 3) participants who are unlikely to have a recurrence during the study~* Participant has a history of cardiac disease including but not limited to heart valve disease or evidence of secondary cardiac damage~* Participant is categorized as class II or greater according to the New York Heart Association (NYHA) functional classification for heart failure~* Participant is unable to refrain from use of prescription or non-prescription drugs or herbal remedies (such as St. John's Wort) during the study~* Participant anticipates using phosphodiesterase (PDE5) inhibitors \[sildenafil (Viagra®), tadalafil (Cialis®), or vardenafil (Levitra®)\] during the study~* Participant consumes excessive amounts of alcohol (more than 3 drinks per day) or caffeine (more than 6 servings a day)~* Participant has had major surgery, donated or lost 1 unit of blood, or participated in another investigational within 4 weeks prior to the study~* Participant has a history of multiple and/or severe allergies, or has had an anaphylactic reaction or intolerance to any drugs or food

- Gender: MALE
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Part I - Sequence ABC (Type: EXPERIMENTAL): Treatment A in Period 1, Treatment B in Period 2, and Treatment C in Period 3
- Part I - Sequence ACB (Type: EXPERIMENTAL): Treatment A in Period 1, Treatment C in Period 2, and Treatment B in Period 3
- Part I - Sequence BCA (Type: EXPERIMENTAL): Treatment B in Period 1, Treatment C in Period 2, and Treatment A in Period 3
- Part I - Sequence BAC (Type: EXPERIMENTAL): Treatment B in Period 1, Treatment A in Period 2, and Treatment C in Period 3
- Part I - Sequence CAB (Type: EXPERIMENTAL): Treatment C in Period 1, Treatment A in Period 2, and Treatment B in Period 3
- Part I - Sequence CBA (Type: EXPERIMENTAL): Treatment C in Period 1, Treatment B in Period 2, and Treatment A in Period 3
- Part II - Sequence DEF (Type: EXPERIMENTAL): Treatment D in Period 1, Treatment E in Period 2, and Treatment F in Period 3
- Part II - Sequence DFE (Type: EXPERIMENTAL): Treatment D in Period 1, Treatment F in Period 2, and Treatment E in Period 3
- Part II - Sequence EFD (Type: EXPERIMENTAL): Treatment E in Period 1, Treatment F in Period 2, and Treatment D in Period 3
- Part II - Sequence EDF (Type: EXPERIMENTAL): Treatment E in Period 1, Treatment D in Period 2, and Treatment F in Period 3
- Part II - Sequence FDE (Type: EXPERIMENTAL): Treatment F in Period 1, Treatment D in Period 2, and Treatment E in Period 3
- Part II -Sequence FED (Type: EXPERIMENTAL): Treatment F in Period 1, Treatment E in Period 2, and Treatment D in Period 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete